Skip to main content
OpenTrials
Completed

NCT Number: NCT05183087

Long-Term Effects of Repetitive, Low-Level Blast Exposure on Special Operations Forces Service Members

This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–45 year

Sex eligibility

Male

Study type

Observational

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

The proposal includes a comprehensive battery of assessments characterized by high-field neuroimaging, proteomics, and experimental cognitive and neurobehavioral evaluations, which will be implemented alongside standardized clinical diagnostic tools. The results will inform the design of a larger trial to validate the diagnostic utility of these biomarkers as well as their ability to predict RLLBE-related clinical outcomes. A secondary aim will be to define the underlying mechanisms, risk and resilience factors, and clinical phenotypes associated with RLLBE.

Biomarkers assessed over the course of a two-day evaluation will include:

  • 3 Tesla Connectome MRI to detect structural disruption of brain networks
  • 7 Tesla MRI to detect functional disruption of brain networks
  • Translocator protein (TSPO) PET - ligand [11C]-PBR28 to detect neuroinflammation
  • Tau PET - ligand [18F]-MK6240 to detect tau deposition
  • Neurocognitive assessments to detect signs of cognitive/behavioral dysfunction
  • Self-report indicators of cognitive/behavioral dysfunction
  • Blood biomarkers to detect evidence of blast injury using proteomics and metabolomics

We hypothesize that a multimodal assessment using Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, cognitive/behavioral tests, proteomics and metabolomics will identify biomarkers of RLLBE-related brain injury.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 25-45 years of age
  • Males, regardless of race or ethnicity
  • Active duty Special Operation Forces
  • History of combat deployment confirmed by Veterans Affairs (VA) or Department of Defense (DOD) records (defined as: while serving in the U.S. military, individual was deployed to a region of conflict)
  • History of combat exposure during any deployment as measured by endorsement of any item on the Combat Exposure Scale (CES)

Exclusion criteria

  • History of moderate or severe traumatic brain injury (TBI) (using the VA/DOD definition: initial Glasgow Coma Scale score < 13, coma duration > ½ hr, post-traumatic amnesia duration > 24 hr, or abnormal structural brain imaging)
  • History of major neurologic disorder such as stroke or spinal cord injury resulting in a significant decrement in functional status or loss of independent living capacity
  • Untreated or unstable severe psychiatric condition (e.g., schizophrenia or bipolar disorder) that is likely to impact study participation or ability to complete study procedures
  • Current severe medical condition (excluding currently diagnosed mild TBI or concussion) that requires long-term treatments (e.g., cancer, diabetes mellitus, human immunodeficiency virus, autoimmune disorders)
  • Any cardiac, respiratory, or other medical condition that may affect cerebral metabolism
  • Benzodiazepines other than lorazepam, desmethyldiazepam and oxazepam within past month
  • MRI contraindications
  • Metal in the body that would make an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye
  • Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
  • Inability to lie supine for up to 2 hours in the MRI scanner, as assessed by physical examination and medical history (e.g., back pain, arthritis)
  • > 300 lbs (weight limit of the MRI table)
  • Prior radiation exposure of ≥ 50 mSv over the past 12 months, in the context of research, as determined by review of DOD medical records (e.g., prior imaging studies) and self-report
  • Any condition which, in the opinion of the Principal Investigator, may cause undue risk to the subject
  • Other: Any condition or characteristic that in the judgment of the Principal Investigator would create a logistical or safety contraindication to enrollment (e.g., shoulder width greater than the bore of the MRI or PET/MRI machines)

Treatment and study plan

3T Connectome MRI

Diagnostic Test

MRI scan of structural connectivity

7 Tesla MRI

Diagnostic Test

MRI scan of functional connectivity

TSPO PET

Diagnostic Test

PET scan of neuroinflammation

Tau PET

Diagnostic Test

PET scan of tau deposition

Cognitive and Behavioral Assessments

Diagnostic Test

Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains

Blood Biomarkers

Diagnostic Test

Blood-based assessments of proteomic and metabolic biomarkers of brain injury

Primary outcomes

  1. Diffusion MRI structural connectivity

    Time frame: Day 1

    measured by white matter tractography

  2. fMRI resting state functional connectivity

    Time frame: Day 2

    measured by default mode network connectivity

  3. PET Neuroinflammation

    Time frame: Day 1

    measured by standardized uptake value ratio of TSPO ligand [11C]PBR28

  4. PET Tau deposition

    Time frame: Day 2

    measured by standardized uptake value ratio of [18F]MK6240

  5. Neurofilament Light Chain

    Time frame: Day 1, after 6-8 hour fasting

    measured by serum concentration of neurofilament light chain

  6. Cognitive Function

    Time frame: Day 1

    measured by the Trail Making Test

  7. Behavioral symptoms

    Time frame: Day 2

    measured by the Neurobehavioral Symptom Inventory

  8. Physical symptoms

    Time frame: Day 2

    measured by the Neurobehavioral Symptom Inventory

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Official study title

Pilot Study of Long-Term Effects of Repetitive, Low-Level Blast Exposure (RLLBE) on Special Operations Forces (SOF) Service Members

Acronym: ReBlast

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jan 10, 2022
Registry last updated
Apr 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.